Gustav Smith
Associate professor
Genetic and In Vitro Inhibition of PCSK9 and Calcific Aortic Valve Stenosis
Author
Summary, in English
The authors investigated whether PCSK9 inhibition could represent a therapeutic strategy in calcific aortic valve stenosis (CAVS). A meta-analysis of 10 studies was performed to determine the impact of the PCSK9 R46L variant on CAVS, and the authors found that CAVS was less prevalent in carriers of this variant (odds ratio: 0.80 [95% confidence interval: 0.70 to 0.91]; p = 0.0011) compared with noncarriers. PCSK9 expression was higher in the aortic valves of patients CAVS compared with control patients. In human valve interstitials cells submitted to a pro-osteogenic medium, PCSK9 levels increased and a PCSK9 neutralizing antibody significantly reduced calcium accumulation.
Department/s
- Cardiology
- Molecular Epidemiology and Cardiology
- EXODIAB: Excellence of Diabetes Research in Sweden
- WCMM-Wallenberg Centre for Molecular Medicine
- Heart Failure and Mechanical Support
- Cardiovascular Epigenetics
- EpiHealth: Epidemiology for Health
Publishing year
2020
Language
English
Pages
649-661
Publication/Series
JACC: Basic to Translational Science
Volume
5
Issue
7
Document type
Journal article
Publisher
Elsevier
Topic
- Cardiac and Cardiovascular Systems
Keywords
- aortic valve interstitial cell
- apolipoprotein B
- calcific aortic valve stenosis
- LDL cholesterol
- lipoprotein(a)
- proprotein convertase subtilisin/kexin type 9
Status
Published
Research group
- Molecular Epidemiology and Cardiology
- Heart Failure and Mechanical Support
- Cardiovascular Epigenetics
ISBN/ISSN/Other
- ISSN: 2452-302X